• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, June 17, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Dual-Laser Approach Transforms Breast Cancer Photothermal Therapy

Bioengineer by Bioengineer
June 10, 2025
in Cancer
Reading Time: 4 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

blank

Breast cancer remains the most frequently diagnosed malignancy among women worldwide, posing persistent challenges despite significant advances in early detection and treatment. The quest for innovative therapies that minimize invasiveness while maximizing efficacy remains relentless. Recently, attention has increasingly shifted toward phototheranostics, a cutting-edge field that harnesses the power of light for the dual purpose of cancer detection and treatment. This approach offers unique advantages, such as non-invasive, real-time imaging paired with precise, localized therapy, enabling clinicians to simultaneously diagnose and combat tumors with greater accuracy.

Among phototheranostic techniques, photothermal therapy (PTT) stands out as a promising modality. PTT utilizes photothermal agents capable of absorbing specific wavelengths of light and converting them efficiently into heat, thereby raising temperatures locally to induce tumor cell death. A critical aspect of this approach lies in the tumor-targeting ability of photothermal agents, which allows selective ablation of malignant tissue while sparing normal cells. However, widespread clinical adoption of PTT has been hampered by several obstacles, chief among them the risk of overheating, which can cause collateral damage to surrounding healthy tissues, and the sometimes insufficient tumor eradication leading to relapse.

Addressing these challenges, a recent collaborative research effort led by Professor ZHANG Pengfei of the Shenzhen Institute of Advanced Technology (SIAT) and his international colleagues has introduced an innovative dual-laser photothermal therapy (DLPTT) strategy. Their work, published in the prestigious journal Proceedings of the National Academy of Sciences, pioneers the use of two wavelengths—808 nm and 1,064 nm—in a sequential treatment protocol designed to enhance tumor ablation while reducing adverse effects. This breakthrough leverages specially engineered near-infrared photothermal agents exhibiting aggregation-induced emission (AIE) properties, which bolster imaging clarity and photothermal conversion efficiency.

.adsslot_jhX0oeWKbS{width:728px !important;height:90px !important;}
@media(max-width:1199px){ .adsslot_jhX0oeWKbS{width:468px !important;height:60px !important;}
}
@media(max-width:767px){ .adsslot_jhX0oeWKbS{width:320px !important;height:50px !important;}
}

ADVERTISEMENT

The DLPTT strategy unfolds in two carefully calibrated stages. Initially, the tumor site undergoes a brief, high-temperature exposure using an 808 nm laser for approximately two minutes, achieving local temperatures around 50 °C. This phase achieves a crucial biological effect: it induces DNA damage in tumor cells and suppresses the expression of heat shock protein 70 (HSP70), a molecular chaperone known to confer thermotolerance. By inhibiting HSP70, this step effectively dismantles a key cellular defense mechanism, rendering cancer cells more vulnerable to subsequent treatment.

Following this priming stage, the therapy transitions to a longer-duration 1,064 nm laser irradiation, maintained at a slightly lower temperature near 43 °C over 13 minutes. This gentler heating phase is optimized to ablate residual tumor cells without provoking excessive inflammation or thermal injury to adjacent healthy tissues. The sequential use of two laser wavelengths capitalizes on their distinct tissue penetration depths and absorption profiles, enabling precise modulation of the tumor microenvironment and maximizing treatment efficacy.

A hallmark of this DLPTT protocol is the integration of second near-infrared window (NIR-II) fluorescence imaging, combined with photoacoustic imaging techniques. NIR-II imaging offers profound advantages, including deeper tissue penetration and significantly reduced scattering, which together produce images with enhanced signal-to-noise ratios. This highly sensitive imaging modality facilitates real-time visualization of tumors, even in deep tissue contexts, allowing clinicians to accurately localize and monitor the response of malignant lesions throughout therapy. Photoacoustic imaging complements this by providing additional anatomical and functional information, enriching the precision of treatment guidance.

Preclinical validation of this approach was conducted using the 4T1 breast cancer mouse model, a well-established system that closely mimics aggressive human breast cancer behavior. The results demonstrated that DLPTT significantly suppressed tumor growth, outstripping conventional single-laser PTT approaches in both effectiveness and safety. Importantly, treated animals showed no marked side effects, with stable body weights and no evident toxicity, underscoring the biosafety profile of this dual-laser regimen.

Further in vivo studies confirmed that DLPTT minimized systemic inflammatory responses, a common complication in thermal therapies. The reduction in inflammatory cytokine production suggests that the dual-laser strategy not only eradicates cancer cells but also preserves normal tissue homeostasis, which is vital for preventing adverse immune reactions and facilitating patient recovery.

Beyond its immediate therapeutic impact, this research also marks a significant advancement in the development of aggregation-induced emission (AIE) materials. AIE luminogens are a novel class of compounds whose fluorescence intensities increase upon aggregation, contrasting with conventional fluorophores that often suffer from quenching. Their use in photothermal agents enhances both imaging clarity and therapeutic precision, positioning them as versatile tools in the expanding field of phototheranostics.

Looking forward, the authors envision a promising future where DLPTT is integrated synergistically with immunotherapy. The combination of precise tumor ablation and immune system modulation could provide a powerful strategy to combat cancer metastasis and recurrence, addressing two of the most daunting challenges in oncology. By dismantling tumor cells locally and simultaneously activating systemic antitumor immunity, such combinatorial therapies hold the potential to redefine cancer care.

This groundbreaking study exemplifies the transformative potential of light-based technologies in modern medicine. By refining photothermal therapy through innovative laser strategies and advanced imaging, it paves the way for minimally invasive, highly effective cancer treatments that prioritize patient safety without compromising therapeutic potency. As research continues to evolve, phototheranostics promises to become a cornerstone of personalized oncology, offering hope for millions affected by breast cancer worldwide.

Subject of Research: Breast cancer photothermal therapy using dual-laser strategy and aggregation-induced emission materials

Article Title: Dual-laser “808 and 1,064 nm” strategy that circumvents the Achilles’ heel of photothermal therapy

News Publication Date: 9-Jun-2025

Web References:
https://doi.org/10.1073/pnas.2503574122

Keywords: Breast cancer, Photothermal therapy, Dual-laser strategy, Near-infrared imaging, Aggregation-induced emission, Phototheranostics, NIR-II fluorescence, Photoacoustic imaging, Tumor ablation, Heat shock protein, Immunotherapy integration

Tags: advancements in breast cancer carebreast cancer photothermal therapydual-laser approach in cancer treatmentinnovative cancer therapieslocalized cancer therapy techniquesminimizing collateral damage in cancer therapynon-invasive cancer treatmentsovercoming PTT challengesphototheranostics for tumor detectionProfessor ZHANG Pengfei research contributionsreal-time imaging in cancer treatmenttumor-targeting photothermal agents

Share12Tweet8Share2ShareShareShare2

Related Posts

blank

Emerging Immunotherapies Revolutionize Lung Cancer Treatment

June 17, 2025
blank

New Genetic Method Expands Access to Hereditary Breast and Ovarian Cancer Risk Testing for Women

June 17, 2025

HKUMed Pioneers Global Liver Cancer Treatment with Innovative Dual Immunotherapy, Enhancing Patient Survival and Securing International Approvals

June 17, 2025

Colorectal Cancer Diagnosis: A Lifesaving Breakthrough or a New Threat for Patients with Multiple Cancers?

June 17, 2025

POPULAR NEWS

  • Green brake lights in the front could reduce accidents

    Study from TU Graz Reveals Front Brake Lights Could Drastically Diminish Road Accident Rates

    159 shares
    Share 64 Tweet 40
  • New Study Uncovers Unexpected Side Effects of High-Dose Radiation Therapy

    76 shares
    Share 30 Tweet 19
  • Pancreatic Cancer Vaccines Eradicate Disease in Preclinical Studies

    70 shares
    Share 28 Tweet 18
  • How Scientists Unraveled the Mystery Behind the Gigantic Size of Extinct Ground Sloths—and What Led to Their Demise

    65 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Emerging Immunotherapies Revolutionize Lung Cancer Treatment

Scientists Develop Innovative Blueprint Merging Rewilding and Agriculture to Combat Biodiversity Crisis

New Genetic Method Expands Access to Hereditary Breast and Ovarian Cancer Risk Testing for Women

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.